|
|
 |
|
Viewing report
|
|
|
|
Industry Outlook: Trends in Respiratory Disease Strategies
Decision Resources, Inc, Nov 2011
The market for respiratory drugs has already proven lucrative for pharmaceutical developers and marketers, supporting multiple blockbuster brands and steady annual sales increases.
Pharmaceutical manufacturers have realized substantial success in the treatment of common respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and respiratory allergies and are poised to unlock the potential of advances in research into rare, often life-threatening respiratory disorders. Challenges nevertheless abound in the respiratory disease market - not the least of which is the loss of patent protection and/or market exclusivity for many top-selling respiratory products.
The constraining effects of these factors will be balanced against several companies’ robust respiratory drug-development pipelines, as well as licensing and acquisition activity that has been critical to the evolution of the respiratory drug market.
Questions answered in this report:
- The respiratory marketplace is highly concentrated. What is the size of this market, and what is its growth trend? Which companies are the leaders based on 2010 sales? Will those rankings change? What opportunities are available to these and other contenders in the respiratory space?
- U.S. physicians report that asthma and COPD caseloads are increasing, but unmet needs are greatest in the management of rarer respiratory diseases with small, relatively stable populations. What brands do U.S. physicians prefer for the treatment of highly prevalent respiratory diseases? What are the greatest unmet needs in managing common and rare respiratory diseases? Will generic inhaled drugs meet a welcoming or reticent audience in the U.S. respiratory market?
- Genericization of blockbuster brands will soon put the brakes on respiratory drug sales growth. What strategies are market-leading companies employing to mitigate the effect of generics competition? Which brands will be toppled from blockbuster status by 2017? Which companies have robust respiratory pipelines stocked with late-stage assets that can replace revenues lost to generics?
Scope:
- Introduction to the respiratory drug market: Market size, market growth, market drivers, product sales, unmet needs.
- Primary research: Results from a Web-based survey of 105 U.S. physicians who manage patients with respiratory diseases: pulmonologists and primary care physicians (PCPs).
- Unmet needs: By disease and need in the clinical setting.
- Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
- Company profiles: GlaxoSmithKline, Sanofi, Merck & Co., Novartis, others.
- Market forecast and outlook: Worldwide and U.S. market size over 2006-2017; key competitors and their market share; future respiratory blockbusters.
- Exhibits: 21 tables/figures showing market data and U.S. physician survey data.
|
|
|
|
